What is the purpose of this trial?
This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread.
National Cancer Institute
Dates: 02/02/2018 - 09/30/2019
Last Updated: 02/05/2018
Study HIC#: 2000021867